BNR — Burning Rock Biotech Income Statement
0.000.00%
- $62.59m
- -$17.62m
- CNY537.44m
- 68
- 59
- 36
- 54
Annual income statement for Burning Rock Biotech, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 382 | 430 | 508 | 563 | 537 |
Cost of Revenue | |||||
Gross Profit | 273 | 314 | 364 | 380 | 363 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 551 | 842 | 1,305 | 1,544 | 1,207 |
Operating Profit | -169 | -412 | -797 | -980 | -669 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -169 | -407 | -796 | -969 | -651 |
Provision for Income Taxes | |||||
Net Income After Taxes | -169 | -407 | -797 | -971 | -654 |
Net Income Before Extraordinary Items | |||||
Net Income | -169 | -407 | -797 | -971 | -654 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -334 | -472 | -797 | -971 | -654 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -32.8 | -68.8 | -76.5 | -93.5 | -63.8 |